# Paragon Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/paragon-genomics

- Industry: Biotechnology
- Headquarters: Hayward, US
- Website: www.paragongenomics.com
- Total disclosed funding: $8M
- Latest round: Series A (Sep 12, 2017)
- Investors on record: 5

## About

Paragon Genomics, Inc. is a biotechnology firm specializing in advanced genomic testing solutions, particularly through its CleanPlex® technology that enhances DNA and RNA sequencing capabilities.Founded in 2015 by Tao Chen and Zhitong Liu, Paragon Genomics, Inc. is headquartered in Hayward, US. The company focuses on targeted genomic testing and has undergone no significant changes in strategy. It secured USD 8.00 mn in SERIES A funding in September 2017, attracting investors such as Cowin Capital and Fosun Industrial Co Limited, and it has completed a total of 1 funding deal.Paragon Genomics offers advanced genomic testing solutions, including its CleanPlex® Multiplex PCR-Based Target Enrichment and Library Preparation Kits for amplicon sequencing. These products facilitate targeted DNA and RNA sequencing for various applications, including infectious diseases and precision oncology. Their CleanPlex technology is known for enabling low-frequency allele detection and RNA gene fusion detection, serving over 300 organizations globally, including academic and biotechnology firms, with a focus on markets outside the United States, especially in Europe and Asia.The company generates revenue primarily through direct sales of its CleanPlex® products and custom next-generation sequencing (NGS) panels, focusing on B2B partnerships. Their products, like the CleanPlex SARS-CoV-2 panels, are tailored for specific genomic analyses, and pricing is based on panel complexity and customization, fostering long-term client relationships.Paragon Genomics plans to leverage its recent USD 8.00 mn funding from the SERIES A round to enhance its product offerings and expand into new markets. The company is developing new products aimed at improving genomic testing efficacy and aims to penetrate several international markets by 2025. The funding will support product innovation and market entry strategies, aligning with the growing global demand for precision genomics.

## Funding rounds

- Series A, Sep 12, 2017, $8M — Cowin Capital, Wisemont Capital, HEDA Ventures, Cloudstone Venture, Fosun Industrial Co Limited

## Investors

- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series A
- Wisemont Capital (https://capitalatlas.ai/funds/wisemont-capital) — Series A
- HEDA Ventures (https://capitalatlas.ai/funds/heda-ventures) — Series A
- Cloudstone Venture (https://capitalatlas.ai/funds/cloudstone-venture) — Series A
- Fosun Industrial Co Limited — Series A